- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05066620
Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial
September 24, 2021 updated by: jianwen guo, MD, Guangzhou University of Traditional Chinese Medicine
An Investigator-initiated and Conducted Multicentre, Prospective, Randomised, Double-blinded Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Chinese Herbal Medicine in Patients With Acute Intracerebral Haemorrhage
TCM is an essential context of the ICH management in Chinese culture.
Given the potential benefits of Chinese herbal medicine FYTF-919 in reducing haematoma and bleeding after acute ICH from fundamental research and small clinical studies, more reliable evidence is required to guide ICH treatment using TCM.
This study aims to determine the effectiveness and safety of TCM in a larger sample of patients with moderate-severe ICH and provide evidence for TCM clinical guidelines on ICH management.
The presumed mechanism of action is in promoting the reabsorption of the haematoma and perihematomal oedema in ICH.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
A multicentre, prospective, randomised, double-blind, placebo-controlled trial to be conducted through hospital network of investigators in China.
A total of 1504 patients with ICH will be recruited from approximately 20-30 hospitals.
Randomised is via a central internet-based system according to block random grouping method stratified by site, neurological severity NIHSS <15 vs ≥15), and haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle) to ensure balance in key prognostic factors.
Endpoint assessment will be blinded to treatment allocation.
The primary aim of this study is to determine the effectiveness and safety of a Chinese herbal medicine FYTF-919 as compared to placebo on functional recovery according to Utility-weighted modified Rankin scale (UW-mRS) at 90 days after acute ICH.
Secondary aims include examining whether the Chinese herbal medicine FYTF-919 leads to positive treatment effect on: 1) Utility-weighted mRS scores at 180 days; 2)Ordinal analysis of 7 levels of mRS at 28 days, 90 days and 180 days; 3) Poor prognosis, defined as mRS 4-6 points at 28 days, 90 days and 180 days; 4) NIHSS score at 7 days and 28 days; 5) Mortality rate at 28 days, 90 days and 180 days; 6) Discharge rate at 28 days; 7) EQ-5D-5L at 28days, 90 days and 180 days; 8) BI at 28 days, 90 days and 180 days; 9) The cerebral edema volume at baseline, 24 hours, 7 days, 14 days or at discharge; 10) The hematoma volume at baseline, 24 hours, 7 days, 14 days or discharge; 11) The incidence of stroke-associated pneumonia (SAP) patients; 12) Clinical pulmonary infection score (CIPS) at the onset of SAP, 3 days, and 7 days, after the occurrence of SAP; 13) Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture at the onset of SAP, 3 days, and 7 days after the occurrence of SAP; 14) Antibiotic usage among patients with SAP.
Study Type
Interventional
Enrollment (Anticipated)
1504
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianwen Guo, MD
- Phone Number: +86-13724899379
- Email: jianwen_guo@qq.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Guangdong Provincial Hospital of Chinese Medicine
-
Contact:
- Jianwen Guo, MD
- Phone Number: +86 13724899379
- Email: jianwen_guo@qq.com
-
Contact:
- Lily Song, PhD
- Phone Number: +86 13916466400
- Email: lsong@georgeinstitute.org.cn
-
Principal Investigator:
- Jianwen Guo
-
Principal Investigator:
- Craig Anderson, The George Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 years;
- Diagnosis of spontaneous ICH, confirmed by brain imaging;
- Presentation within 48 hours of symptom onset (or last seen well);
- Meet any of the following criteria: a) NIHSS ≥8, or b) GCS 7-14;
- Provide written informed consent by patient (or approved surrogate);
Exclusion Criteria:
- ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischaemic stroke), or secondary to presumed cerebrovascular amyloidosis, or secondary to reperfusion treatment for ischaemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment.
- Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment;
- Other medical illness that will interfere with outcome assessments and follow-up (e.g. known significant pre-stroke disability [modified Rankin scale {mRS} scores 4-5], advanced cancer and renal failure);
- Known definite contraindication to the Chinese herbal medicine;
- Women who are known to be pregnant or lactating;
- Currently participating in another trial which would interfere with outcome assessments.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
Chinese herbal medicine FYTF-919: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
|
Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
Other Names:
|
Placebo Comparator: Control group
Placebo treatment: Oral liquid 33ml TID (or patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
|
Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Utility-weighted modified Rankin scale scores
Time Frame: 90 days after the treatment started
|
Utility-weighted modified Rankin scale scores.
The value range from 0 to 10: higher scores mean a better outcome.
|
90 days after the treatment started
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Utility-weighted mRS scores
Time Frame: 180 days after the treatment started
|
Utility-weighted modified Rankin scale scores.
The value range from 0 to 10: higher scores mean a better outcome.
|
180 days after the treatment started
|
7 levels of mRS
Time Frame: 28 days, 90 days and 180 days after the treatment started
|
Ordinal analysis of 7 levels of mRS.
The value range 0-6: higher scores mean a worse outcome.
|
28 days, 90 days and 180 days after the treatment started
|
Poor prognosis rate
Time Frame: 28 days, 90 days and 180 days after the treatment started
|
Binary variable: 1 means mRS 4-6 points; 0 means mRS is 0-3 points.
|
28 days, 90 days and 180 days after the treatment started
|
NIHSS score
Time Frame: 7 days and 28 days after the treatment started
|
National Institute of Health Stroke Scale Score.
The value range 0-42: higher scores mean a worse outcome.
|
7 days and 28 days after the treatment started
|
Mortality rate
Time Frame: 28 days, 90 days and 180 days
|
Mortality rate
|
28 days, 90 days and 180 days
|
Discharge rate
Time Frame: 28 days after the treatment started
|
Discharge rate
|
28 days after the treatment started
|
European Quality of Life 5-dimensional questionnaire (EQ-5D-5L)
Time Frame: 28 days, 90 days and 180 days after the treatment started
|
The EQ-5D comprises five dimensions of health: mobility, ability to self-care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. .
EQ-5D-5L, includes five levels of severity for each dimension (no problems, slight problems, moderate problems, severe problems, and extreme problems).
The value range 0-100: higher scores mean a worse outcome.
|
28 days, 90 days and 180 days after the treatment started
|
BI
Time Frame: 28 days, 90 days and 180 days after the treatment started
|
Barthel index.
The value range 0-100: higher scores mean a better outcome.
|
28 days, 90 days and 180 days after the treatment started
|
The cerebral edema volume
Time Frame: Baseline, 24 hours, 7 days, 14 days or at discharge
|
The cerebral edema volume
|
Baseline, 24 hours, 7 days, 14 days or at discharge
|
The hematoma volume
Time Frame: Baseline, 24 hours, 7 days, 14 days or discharge
|
The hematoma volume
|
Baseline, 24 hours, 7 days, 14 days or discharge
|
SAP
Time Frame: Baseline, 24 hours, 7 days, 14 days or discharge
|
The incidence of stroke-associated pneumonia patients
|
Baseline, 24 hours, 7 days, 14 days or discharge
|
CPIS
Time Frame: The onset of SAP, 3 days and 7 days after the occurrence of SAP
|
Clinical pulmonary infection score.
The value range 0-12: higher scores mean a worse outcome.
|
The onset of SAP, 3 days and 7 days after the occurrence of SAP
|
Pulmonary infection
Time Frame: The onset of SAP, 3 days and 7 days after the occurrence of SAP
|
Diagnosed by using the Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture
|
The onset of SAP, 3 days and 7 days after the occurrence of SAP
|
Antibiotic usage
Time Frame: The onset of SAP, 3 days and 7 days after the occurrence of SAP
|
Antibiotic usage among patients with SAP
|
The onset of SAP, 3 days and 7 days after the occurrence of SAP
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Craig Anderson, MD, The George Institute for Global Health, Australia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2021
Primary Completion (Anticipated)
December 1, 2024
Study Completion (Anticipated)
January 1, 2025
Study Registration Dates
First Submitted
September 7, 2021
First Submitted That Met QC Criteria
September 24, 2021
First Posted (Actual)
October 4, 2021
Study Record Updates
Last Update Posted (Actual)
October 4, 2021
Last Update Submitted That Met QC Criteria
September 24, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020B1111100009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Data can be shared with bona fide researchers after the publication of the main results, based on a submitted protocol to the research office of The George Institute for Global Health, Sydney Australia.
IPD Sharing Time Frame
Data sharing will be available from 12 months after the publication of the main results.
IPD Sharing Access Criteria
- The data sharing will be only for the purposes of health and medical research and within the constraints of the consent under which the data were originally gathered.
- The Custodian of the Collection will not consider any Proposals for data sharing that unblind, or potentially unblind, randomised comparisons in active / ongoing trials.
- Requesters should be employees of a recognised academic institution, health service organisation, commercial research organisation or from the pharmaceutical industry. Requesters must have experience in medical research.
- Requesters must be able to demonstrate through their peer review publications in the area of interest their ability to carry out the proposed use of the requested dataset from a Collection.
- The Requesters must not have a conflict of interest that may potentially influence their interpretation of any analyses.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
CellMed AG, a subsidiary of BTG plc.TerminatedIntracerebral Hemorrhage (ICH)Germany
-
Tang-Du HospitalRecruitingIntracerebral Hemorrhage;Circulating ExosomesChina
Clinical Trials on Chinese herbal medicine FYTF-919
-
Guangzhou University of Traditional Chinese MedicineCompletedPlacebo EvaluateChina
-
Center for Integrated CareUniversity of California, San Francisco; University of UtahRecruitingCoronavirus InfectionUnited States
-
Chang Gung Memorial HospitalUnknownEarly-stage Breast CancerTaiwan
-
Shengjing HospitalRecruitingPlasma Cell MastitisChina
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Putuo District Center HospitalCompletedType 2 Diabetes MellitusChina
-
Hong Kong Baptist UniversityRecruiting
-
Heilongjiang University of Chinese MedicineNot yet recruitingIn Vitro FertilizationChina
-
China Academy of Chinese Medical SciencesUnknownPrimary InsomniaChina
-
Chinese University of Hong KongUniversity of Maryland; National Center for Complementary and Integrative Health...CompletedIrritable Bowel SyndromeChina
-
Taipei City HospitalNational Yang Ming UniversityCompletedLiver DysfunctionTaiwan